Bavarian Nordic Deal Opens Up Potential China Market For RSV Vaccine
Company Lags Behind Big Players, But Could Seize Asian Opportunity
Bavarian Nordic 's RSV vaccine is about to begin its Phase III trials, which could mean a launch as soon as 2024 • Source: Alamy 
